Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia.
about
Pleiotropic effects of statinsRisk factors in coronary atherosclerosis athero-inflammation: the meeting pointThe Myocardial Ischemia Reduction with Acute Cholesterol Lowering (MIRACL) trial: a new frontier for statins?The "Statinth" wonder of the world: a panacea for all illnesses or a bubble about to burst.Potential role of ultrafine particles in associations between airborne particle mass and cardiovascular health.Cytokines in Schizophrenia: Hope or Hype?C-reactive protein (CRP)-lowering agentsStatin Use and Risk of Cirrhosis and Related Complications in Patients with Chronic Liver Diseases: a Systematic Review and Meta-analysis.Prevalence of coronary artery disease risk factors in Iran: a population based survey.Ambient particulate matter, C-reactive protein, and coronary artery disease.Statins and inflammatory markers.Basic science review: Statin therapy--Part I: The pleiotropic effects of statins in cardiovascular disease.Matrix metalloproteinases and atherosclerotic plaque instability.Lipid-lowering therapies in the management of acute coronary syndromes.Inflammation in end-stage renal disease: sources, consequences, and therapy.Inflammatory bio-markers and cardiovascular risk prediction.High sensitivity C-reactive protein: an emerging role in cardiovascular risk assessment.The role of matrix metalloproteinases in vascular disease.Statins and C-reactive protein: considering a novel marker of cardiovascular risk.Role of inflammation in cardiovascular disease: how to use C-reactive protein in clinical practice.C-reactive protein and risk of cardiovascular disease: evidence and clinical application.Isoprenoid metabolism and the pleiotropic effects of statinsEffect of pretreatment of ezetimibe/simvastatin on arterial healing and endothelialization after drug-eluting stent implantation in a porcine coronary restenosis model.Short-term effect of fenofibrate on C-reactive protein: A meta-analysis of randomized controlled trials.C-reactive protein and cardiovascular disease: new insights from an old molecule.Effect of atorvastatin on C-reactive protein and benefits for cardiovascular disease in patients with type 2 diabetes: analyses from the Collaborative Atorvastatin Diabetes TrialAir pollution and inflammation (interleukin-6, C-reactive protein, fibrinogen) in myocardial infarction survivors.Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol.Microalbuminuria and C-reactive protein: similar messengers of cardiovascular risk?Anti-inflammatory effects of statins: clinical evidence and basic mechanisms.The association of prior statin use in septic shock treated with early goal directed therapy.Statins and biomarkers of inflammation.The GALAXY Program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk.Statins as first-line therapy for acute coronary syndrome?Non-antiarrhythmic drugs in atrial fibrillation: a review of non-antiarrhythmic agents in prevention of atrial fibrillation.Regression or reduction in progression of atherosclerosis, and avoidance of coronary events, with lovastatin in patients with or at high risk of cardiovascular disease: a review.Statin therapy is associated with improved patency of autogenous infrainguinal bypass grafts.Cardiac disease in chronic obstructive pulmonary diseaseComprehensive genetic analysis of the platelet activating factor acetylhydrolase (PLA2G7) gene and cardiovascular disease in case-control and family datasets.An Evaluation of the Clinical Evidence on the Role of Inflammation and Oxidative Stress in Smoking-Mediated Cardiovascular Disease.
P2860
Q24647863-96A8D661-4834-43E6-B59B-913BCD25610AQ24793107-8796F567-CDAB-4EB7-87E6-68DEAF7A9616Q24793160-C9DC7B34-E204-4098-8BED-BF8E276C84BDQ24796000-68EA0DAF-27F5-445A-8741-3A0ECF209931Q24815147-FD08D480-E392-4159-ACC2-580894378A9FQ26750430-DE6F23A9-4CBA-4F61-9BD4-3B2D2D83F21BQ28200344-0797F703-A81B-4CBC-960E-C5CB875F5AF1Q30234533-0F2FF443-7626-4505-A816-A9C268176F5DQ33304394-4C2DEEE5-8124-4BED-83D8-B87F5201CFDFQ34434076-E130437A-0E5F-400E-874D-9144CC4194ADQ34482145-12E29ED6-21B7-4857-A281-821B0B95DDFAQ34618889-6EA03489-1842-42A9-8DBF-B78EE7E0EE6EQ34655385-D9B61C0D-02E3-4603-9C1D-8510F1F3806CQ34674174-179D8FD8-E5FE-4964-A1AA-86FC9ABCE143Q34928704-02069AE6-5CD6-4CD2-A0B9-49202CEFB7D6Q34941391-9C443EC5-A4D5-47EF-B15D-AE70F3422225Q34973446-71F213E9-E1B9-4E87-8FB1-F7068066D384Q34981650-DC25996E-F7A5-4FC1-A6D1-8675A3E250D7Q34989692-2CEE5877-1F67-45AC-AA3E-FB6AA43D041FQ34989707-1FBE9DC2-453E-43F0-8F13-C86FE4C6C7E1Q35197097-917431CD-B0A6-4FE4-B371-23588C250A88Q35197114-A4C86BE3-AD45-437E-A760-CB3D71C3EA1FQ35215336-6CACB9B0-2255-4BAD-9EFB-FC4D0BD9531EQ35386431-E151684A-034E-4103-9639-C338E5CBCD00Q35562701-9432F1FD-0B10-4ED8-AB00-3A222DFF58AFQ35757048-13E55BCE-1498-4786-BAF6-32E0C1AC7573Q35879702-BDE575F4-52EA-4256-8EB2-6DC5D48F67C4Q36242351-32508FE4-46E6-406E-BEA5-F5126593F204Q36255435-0A8E8546-2F77-49C1-B419-D8DE0228EA57Q36337932-5BD1EFF0-5477-41F4-9EDB-D2D91BB2BEE0Q36566297-42DB8876-9A45-48AA-8D75-1F35B7A9C900Q36684187-418DF0E9-6AFE-4F14-963B-3E2FD338D91BQ36752067-75987DC8-C544-4FAD-B171-6B572EDC7071Q36768488-DB6F1389-6CB0-4256-AB01-000B7953E9F9Q36841963-A3B11AE3-E46C-434A-982A-1B2F927811AAQ36913015-305ABEA2-1D49-46D0-B751-6DEC3DC3D6D9Q37098888-24C74B16-F604-4905-9D29-C5D638B1ACDFQ37103712-C1FB62EA-F487-44D7-8F24-072BD93F8B25Q37120610-6654A945-3194-48D9-B30B-6F07A99A5115Q37207355-248B453E-54FC-42A6-A684-14523B2AADC3
P2860
Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Rapid reduction in C-reactive ...... primary hypercholesterolemia.
@ast
Rapid reduction in C-reactive ...... primary hypercholesterolemia.
@en
type
label
Rapid reduction in C-reactive ...... primary hypercholesterolemia.
@ast
Rapid reduction in C-reactive ...... primary hypercholesterolemia.
@en
prefLabel
Rapid reduction in C-reactive ...... primary hypercholesterolemia.
@ast
Rapid reduction in C-reactive ...... primary hypercholesterolemia.
@en
P2093
P1433
P1476
Rapid reduction in C-reactive ...... primary hypercholesterolemia.
@en
P2093
P304
P356
10.1161/01.CIR.103.9.1191
P407
P577
2001-03-01T00:00:00Z